BioNTech
strong momentum built on two decades of innovation i clinical | BioNTech
Company
Deck Type
Sector
Industry
Deck date
June 2022
Slide
10 of 156
Related slides by other companies
Apollomics
SPAC
September 2022
pipeline of early clinical and preclinical programs | Apollomics
OmniAb
Results
March 2023
performance indicators | OmniAb
AstraZeneca
Investor Presentation
March 2022
| AstraZeneca
Nuvalent
Investor Presentation
January 2024
track record of success resource efficient execution and value creation across an expanding portfolio wholly owned programs emergence from first clinical proof of concept second proof of concept first pivotal study disclosed parallel lead programs initiated two global phase studies demonstrated clinical proof of concept and alk for alk program presented preclinical profiles demonstrated clinical proof of concept initiated phase with supporting desired target product for program registrational intent disclosed third novel program advanced her program towards listed her ended with approximately in cash cash equivalents and marketable securities unaudited with potential to deliver multiple transformative catalysts within cash runway window into preliminary unaudited estimate only as the date this presentation subject to change following completion year end closing procedures does not present all information necessary for an understanding financial position as a | Nuvalent
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Results
March 2022
Investor Day
February 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights